P2RX7 and myeloid sarcoma: The use of P2X7 receptor antagonists, such as periodate-oxidized ATP and Brilliant Blue G (BBG), for the treatment of the neurodegenerative phase of MS has been patented (EP1655032 B1), providing novel tools for clinical and research purposes.